- Headquarters: Israel
- Founded: 2010
- kitovpharma.com
Kitov Pharmaceuticals ACQUIRES additional 27% stake in TyrNovo, a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders
After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.
- "Based on the pre-clinical results generated to date, we are receiving solid preliminary interest from potential strategic partners for NT219, which presents a novel, first-in-class mechanism of action in the oncology field."
- "Since early 2017, NT219 demonstrated impressive efficacy results including in combination with Keytruda, where it converted non-responding tumors to responders and blocked tumor progression in an immuno-oncology preclinical model. We are pleased to have negotiated the opportunity for Kitov to increase its stake in TyrNovo. We are committed to the development of NT219, which we believe is a highly attractive asset for Kitov's shareholders in the growing field of oncology"
No comments:
Post a Comment